股票行情快报：五洲医疗（301234）2月10日主力资金净卖出362.88万元

Core Viewpoint - Wuzhou Medical (301234) reported a slight increase in stock price but faced significant declines in net profit and net profit after deducting non-recurring items in the latest financial results [1][2]. Financial Performance - For the first three quarters of 2025, Wuzhou Medical achieved a main operating revenue of 345 million yuan, a year-on-year increase of 0.82% [2]. - The net profit attributable to shareholders was 18.51 million yuan, reflecting a year-on-year decrease of 46.09% [2]. - The net profit after deducting non-recurring items was 14.82 million yuan, down 45.3% year-on-year [2]. - In Q3 2025, the company reported a single-quarter main operating revenue of 128 million yuan, a decline of 1.51% year-on-year [2]. - The single-quarter net profit attributable to shareholders was 7.99 million yuan, down 36.39% year-on-year [2]. - The single-quarter net profit after deducting non-recurring items was 6.48 million yuan, a decrease of 28.01% year-on-year [2]. - The company's debt ratio stood at 12.32%, with investment income of 3.67 million yuan and financial expenses of -2.07 million yuan [2]. - The gross profit margin was reported at 14.22% [2]. Business Model - Wuzhou Medical specializes in the research, production, and sales of disposable sterile infusion medical devices, as well as integrated supply of other diagnostic and nursing medical supplies [2]. - The company primarily operates through an "ODM + integrated supply" model to meet the one-stop procurement needs of foreign medical device brand companies [2].